Eikon Therapeutics Inc. (EIKN) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.1M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While EIKN currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.59) and Max Pain ($5.62) forces dealer call-delta covering toward $18.27.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Eikon Therapeutics Inc. (EIKN) dropped -3.43% to $5.35, trading at 3% of its 52-week range ($5.01 – $17.4). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile suppo
EIK1001 Clinical Update:Updated data from the open-label TeLuRide-005 trial evaluating TLR7/8 dual-agonist EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy in participants with
Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies wit
Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropria
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EIKN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EIKN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Eikon Therapeutics Inc. (EIKN) ranks #412 by composite RQD confidence (47/100, grade D) and #523 by equity capitalization ($289.8M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. EIKN currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EIKN
ACTIVE
Eikon Therapeutics Inc. | D | 47/100 | — | — | — | -3.43% | $289.8M | Benchmark Subject |
| SABS SAB Biotherapeutics Inc. | D | 45/100 | 22.1x | — | -27.4% | +0.94% | $293.9M | /sabs-vs-eikn → |
| CABA Cabaletta Bio Inc. | D- | 42/100 | — | — | -35.0% | +4.28% | $268.7M | /caba-vs-eikn → |
| IPSC Century Therapeutics Inc. | E | 28/100 | — | — | -14.1% | -2.67% | $264.4M | /ipsc-vs-eikn → |
| AGEN Agenus Inc. | E | 26/100 | — | 96.0% | -35.0% | -0.56% | $320.2M | /agen-vs-eikn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eikon Therapeutics Inc. (EIKN) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, EIKN closed FY2025 with $594.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $594.7M | — |
As of 2026-11-01, Eikon Therapeutics Inc. (NASDAQ: EIKN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $5.35 (-3.43% 1D, market cap $289.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EIKN ranks #412 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EIKN carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SABS (SAB Biotherapeutics Inc.) holds a D grade (45/100 RQD, P/E 22.1x, ROIC -27.4%, cap $293.9M) and CABA (Cabaletta Bio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $268.7M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).
Per EIKN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861123), Eikon Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $594.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
EIKN last traded at $5.35 (-3.43% on volume of 575,799 shares), positioning the stock -37.72% below its 50-day simple moving average ($8.59) and -48.71% below its 200-day simple moving average ($10.43). Across its 52-week range of $5.01 to $17.40, EIKN sits at the 2.7% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.68 to $6.02).
Why EIKN Stock dropped -3.43% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.